Sunao Shoji1,2, Osamu Ukimura3, Andre Luis de Castro Abreu1, Arnaud Marien1, Toru Matsugasumi1, Duke Bahn1, Inderbir S Gill1. 1. Center for Prostate Cancer Focal Therapy, Keck School of Medicine, USC Institute of Urology, University of Southern California, 1441 Eastlake Ave, Suite 7416, Los Angeles, CA, 90089, USA. 2. Department of Urology, Tokai University Hachioji Hospital, Hachioji, Japan. 3. Center for Prostate Cancer Focal Therapy, Keck School of Medicine, USC Institute of Urology, University of Southern California, 1441 Eastlake Ave, Suite 7416, Los Angeles, CA, 90089, USA. ukimura@usc.edu.
Abstract
PURPOSE: To report our 11-year experience of Active Surveillance (AS) program focusing on modern transrectal ultrasound (TRUS)-based monitoring of targeted biopsy-proven cancer lesion. METHODS: Consecutive patients on AS, who had targeted biopsy-proven lesion followed by at least a repeat surveillance biopsy and three times TRUS monitoring of the identical visible lesion, were included. Doppler grade of blood flow signal within the lesion was classified from grade 0 to 3. Biopsy-proven progression was defined as upgrade of Gleason score or 25% or greater increase in cancer core involvement. RESULTS: Fifty patients were included in this study. Clinical variables (median) included age (61 years), clinical stage (T1c, 42;T2, 8), PSA (4.6 ng/ml), and Gleason score (3 + 3, n = 41;3 + 4, n = 9). Of the 50 patients, 34 demonstrated pathological progression at a median follow-up of 4.4 years. In comparing between without (n = 16) and with (n = 34) pathological progression, there were significant differences in cancer core involvement at entry (p = 0.003), the major axis diameter (p = 0.001) and minor axis diameter (p = 0.001) of the visible lesion at entry, increase in the major axis diameter (p = 0.005) and minor axis diameter (p = 0.013), and upgrade of Doppler grade (p < 0.0001). In multivariate analysis for predicting pathological progression, the increase (≥25%) in diameter of biopsy-proven lesion (hazard ratio, 15.314; p = 0.023) and upgrade of Doppler grade (hazard ratio, 37.409; p = 0.019) were significant risk factors. CONCLUSIONS: Longitudinal monitoring of the TRUS-visible biopsy-proven cancer provides a new opportunity to perform per-lesion-based AS. The increase in diameter and upgrade of Doppler grade of the lesion were significant risk factors for biopsy-proven progression on AS.
PURPOSE: To report our 11-year experience of Active Surveillance (AS) program focusing on modern transrectal ultrasound (TRUS)-based monitoring of targeted biopsy-proven cancer lesion. METHODS: Consecutive patients on AS, who had targeted biopsy-proven lesion followed by at least a repeat surveillance biopsy and three times TRUS monitoring of the identical visible lesion, were included. Doppler grade of blood flow signal within the lesion was classified from grade 0 to 3. Biopsy-proven progression was defined as upgrade of Gleason score or 25% or greater increase in cancer core involvement. RESULTS: Fifty patients were included in this study. Clinical variables (median) included age (61 years), clinical stage (T1c, 42;T2, 8), PSA (4.6 ng/ml), and Gleason score (3 + 3, n = 41;3 + 4, n = 9). Of the 50 patients, 34 demonstrated pathological progression at a median follow-up of 4.4 years. In comparing between without (n = 16) and with (n = 34) pathological progression, there were significant differences in cancer core involvement at entry (p = 0.003), the major axis diameter (p = 0.001) and minor axis diameter (p = 0.001) of the visible lesion at entry, increase in the major axis diameter (p = 0.005) and minor axis diameter (p = 0.013), and upgrade of Doppler grade (p < 0.0001). In multivariate analysis for predicting pathological progression, the increase (≥25%) in diameter of biopsy-proven lesion (hazard ratio, 15.314; p = 0.023) and upgrade of Doppler grade (hazard ratio, 37.409; p = 0.019) were significant risk factors. CONCLUSIONS: Longitudinal monitoring of the TRUS-visible biopsy-proven cancer provides a new opportunity to perform per-lesion-based AS. The increase in diameter and upgrade of Doppler grade of the lesion were significant risk factors for biopsy-proven progression on AS.
Entities:
Keywords:
Active surveillance; Biopsy; Imaging; Prostate cancer; Transrectal ultrasound
Authors: Hong Wei Zhao; Jun Hang Luo; Hui Xiong Xu; Dao Hu Wang; Ying Rong Lai; Mian Ni Chen; Jian Yao Lv; Xiao Yan Xie; Ming De Lu; Wei Chen Journal: Urol Int Date: 2011-08-11 Impact factor: 2.089
Authors: Anthony V D'Amico; Richard Whittington; S Bruce Malkowicz; Kerri Cote; Marian Loffredo; Delray Schultz; Ming-Hui Chen; John E Tomaszewski; Andrew A Renshaw; Alan Wein; Jerome P Richie Journal: Cancer Date: 2002-07-15 Impact factor: 6.860
Authors: Nathan Lawrentschuk; Ants Toi; Gina A Lockwood; Andrew Evans; Antonio Finelli; Martin O'Malley; Myles Margolis; Sangeet Ghai; Neil E Fleshner Journal: J Urol Date: 2009-12 Impact factor: 7.450
Authors: Yousef Mazaheri; Hedvig Hricak; Samson W Fine; Oguz Akin; Amita Shukla-Dave; Nicole M Ishill; Chaya S Moskowitz; Joanna E Grater; Victor E Reuter; Kristen L Zakian; Karim A Touijer; Jason A Koutcher Journal: Radiology Date: 2009-08 Impact factor: 11.105
Authors: Mark S Soloway; Cynthia T Soloway; Steve Williams; Rajinikanth Ayyathurai; Bruce Kava; Murugesan Manoharan Journal: BJU Int Date: 2007-09-10 Impact factor: 5.588
Authors: Alvin R Cabrera; Fergus V Coakley; Antonio C Westphalen; Ying Lu; Shoujun Zhao; Katsuto Shinohara; Peter R Carroll; John Kurhanewicz Journal: Radiology Date: 2008-05 Impact factor: 11.105
Authors: Michael L Eisenberg; Janet E Cowan; Benjamin J Davies; Peter R Carroll; Katsuto Shinohara Journal: Urol Oncol Date: 2009-04-11 Impact factor: 3.498